JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease

Abstract

In this clinical practice guideline, the recommendations and levels of evidence are classified in accordance with the updated JCS statement, encompassing the estimated benefit in proportion to risk (Tables 1,2).

Sixty years of the Bruce protocol: reappraising the contemporary role of exercise stress testing with electrocardiographic monitoring

“…4,13,15,16,39,57,58 These resonate deeply with current recommendations regarding chronic coronary syndromes where the utility of ExECG in the diagnosis of IHD has progressively been superseded by imaging modalities because of issues related to both sensitivity and specificity. 4,16,59,60 Interestingly, while data reinforce the limitations of this examination in the assessment of suspected IHD (a hitherto classical indication), contemporary guidelines also acknowledge the potential of ExECG in several scenarios (Fig. 1).…”

“…4,16,57 Albeit this, in this setting, its role has progressively focused on providing a comprehensive assessment able to detail relevant ancillary data regarding several facets of the cardiovascular response to physical effort. 16,59,60 Cardiac rehabilitation and exercise prescription Given its integrative nature, ExECG may be particularly relevant in the evaluation of the exercise response in patients with CVD. 4,16,26,76,77 This encompasses the detection of possible cardiovascular abnormalities (for symptoms, but also arrhythmias and the BP response) while also allowing for an objective measure of the individual's functional capacity.…”

Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome ― A Post Hoc Secondary Analysis of STOPDAPT-2 ACS ―

“…1 Conversely, for patients with stable coronary artery disease, the use of high-intensity statins is recommended only for those patients with a higher ischemic risk. 2, 3 In these guidelines, the recommended target value of LDL-C is set as <70 mg/dL, and, if not achieved, further intensive therapy, such as ezetimibe or PCSK9 inhibitors, should be considered to meet the LDL-C target. For patients with ACS, several overseas studies (e.g., PROVE-IT, A to Z, IDEAL, and SEARCH) confirmed the efficacy of highintensity statins compared with a standard dose of statins.…”

Role of the renin–angiotensin system in the pathophysiology of coronary heart disease and heart failure: Diagnostic biomarkers and therapy with drugs and natural products

“…The guidelines on coronary artery disease recommend diseasespecific combination therapies with the attention on concomitant diseases such as hypertension, dyslipidemia, diabetes, and kidney injury (Nakano et al, 2022) (Arnett et al, 2019). In case of hypertension, RAS-inhibitors are the leading drugs.…”